POEMS syndrome is a rare blood disorder in which abnormal plasma cells produce a protein that damages multiple organ systems throughout the body. The name is an acronym for its five hallmark features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes. With an estimated prevalence of about 0.3 per 100,000 people, it is frequently misdiagnosed for years because its wide-ranging symptoms mimic other conditions.
What Causes POEMS Syndrome
At its core, POEMS syndrome is driven by a small number of abnormal plasma cells in the bone marrow. Plasma cells are immune cells that normally produce antibodies, but in POEMS they become clonal, meaning they multiply from a single defective cell and churn out an abnormal protein (called an M-protein) that is almost always of the lambda light-chain type. The amount of this protein is usually modest, which is one reason the disorder can fly under the radar on routine blood tests.
The real damage comes from a signaling molecule called vascular endothelial growth factor, or VEGF. In healthy people, VEGF helps build new blood vessels and regulate their permeability. In POEMS, it is massively overproduced. That flood of VEGF makes tiny blood vessels throughout the body leaky and stimulates abnormal new vessel growth, which helps explain why the syndrome hits so many different organs at once: nerves, skin, liver, endocrine glands, and more. Serum VEGF levels above 1,000 pg/mL, combined with the characteristic nerve damage and a lambda-type plasma cell disorder, are virtually diagnostic, with 100% sensitivity and 93% specificity.
The Five Features of the Acronym
Polyneuropathy
Nerve damage is the defining symptom and often the reason people first seek medical attention. It typically starts with tingling, numbness, and a cold sensation in the feet, then gradually moves upward. Motor weakness follows the sensory symptoms: difficulty climbing stairs, rising from a chair, or gripping objects firmly. Over time, the weakness usually becomes more disabling than the sensory loss. Unlike some other neuropathies, POEMS does not affect the cranial nerves (the nerves controlling the face, eyes, and swallowing), with the exception that some patients develop papilledema, a swelling of the optic nerve visible on an eye exam.
Organomegaly
Enlargement of the liver, spleen, or lymph nodes is reported in 50 to 78% of patients at the time of diagnosis. The liver is the most commonly affected organ, involved in roughly half of cases, followed by the spleen and abdominal lymph nodes. The enlargement is typically mild, and massively bulky organs are unusual.
Endocrinopathy
Hormonal disruption is extremely common. By the end of follow-up in one study, 92% of patients had at least one endocrine abnormality. The most frequent is hypogonadism (low sex hormones), found in about 68% of patients. In men this shows up as low testosterone and erectile dysfunction; in women, irregular periods. Other common findings include elevated prolactin levels (56%), hypothyroidism (54%), abnormal blood sugar or diabetes (24%), and adrenal insufficiency (17%). Most patients develop problems in more than one hormonal axis, and some of these abnormalities resolve with successful treatment of the underlying disease, though hypogonadism tends to persist. Only about 14% of patients with hypogonadism see it resolve on its own.
Monoclonal Protein
Every patient with POEMS has a detectable monoclonal protein, though finding it sometimes requires sensitive tests called immunofixation on both blood and urine samples. The protein is almost always lambda-type. Its concentration is typically low, with a median around 1.0 mg/dL, so standard screening tests for blood cancers can easily miss it.
Skin Changes
More than 75% of patients have visible skin findings at diagnosis. The most common are diffuse darkening of the skin (hyperpigmentation) and small red-purple spots called hemangiomas, especially on the trunk and upper limbs. Other changes include excess hair growth on the face or extremities, bluish discoloration of the fingers and toes, white nails, flushing, and clubbing of the fingertips.
How POEMS Is Diagnosed
Because no single test confirms the diagnosis, doctors use a criteria-based system. The five major criteria are polyneuropathy, a clonal plasma cell disorder, bone lesions that appear dense (sclerotic) on imaging, elevated VEGF, and the presence of a related condition called Castleman disease. The minor criteria include organomegaly, endocrinopathy, skin changes, papilledema, fluid overload (such as swelling in the legs or fluid around the lungs), and an elevated platelet count.
A formal diagnosis requires three major criteria, two of which must be polyneuropathy and a clonal plasma cell disorder, plus at least one minor criterion. This framework exists because the syndrome overlaps with several other conditions, and meeting these thresholds helps distinguish it from mimics.
Why It Gets Mistaken for CIDP
The most common misdiagnosis is chronic inflammatory demyelinating polyneuropathy, or CIDP, a more familiar nerve condition that also causes progressive weakness and sensory loss. Both disorders damage the myelin coating of nerves, so they can look similar on nerve conduction studies. However, there are important differences under the microscope: nerve biopsies in POEMS show more widespread nerve fiber loss and a striking increase in tiny blood vessels in the tissue surrounding the nerve, a direct consequence of VEGF overproduction. CIDP biopsies, by contrast, show more localized inflammation inside the nerve and characteristic layered structures called onion bulbs that are essentially absent in POEMS.
The distinction matters because CIDP is treated with immune-suppressing therapies like intravenous immunoglobulin, which do not help POEMS. Patients misdiagnosed with CIDP who fail to improve on standard therapy should be screened for a monoclonal protein and elevated VEGF.
Treatment Approaches
Treatment targets the underlying abnormal plasma cells rather than the individual symptoms. The approach depends largely on how widespread the disease is.
When bone lesions are limited to one or a few spots, radiation therapy directed at those lesions can be effective. This localized approach can lead to significant improvement in nerve function and other symptoms over the following months.
When the disease is more widespread, systemic therapy is needed. Chemotherapy regimens are the standard first step. For patients who are young and fit enough, a bone marrow stem cell transplant may follow. This involves collecting a patient’s own stem cells, using high-dose chemotherapy to wipe out the diseased marrow, and then reinfusing the healthy stem cells to rebuild it. Physical therapy plays an important supporting role throughout treatment, helping patients regain strength and mobility as nerve damage slowly improves.
Treatment can ease symptoms significantly, but it does not cure the disease. Relapses can occur, and second-line options are available when they do.
Long-Term Outlook
POEMS syndrome is serious, but survival has improved considerably with modern treatments. In a recent study of patients treated with a first-line chemotherapy-based regimen, the estimated five-year overall survival rate was about 89%. Patients who received maintenance therapy after their initial treatment had significantly longer periods before the disease progressed compared to those who did not.
Nerve recovery is often the slowest piece. While many patients see meaningful improvement, it can take months to years, and some residual weakness or numbness may persist. Hormonal abnormalities frequently require ongoing replacement therapy, particularly for low sex hormones and thyroid function. Regular monitoring of VEGF levels helps track whether the disease is responding to treatment or beginning to return, since VEGF drops reliably when therapy is working.